Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5345_Библиотеки_им_академика_М_И_Перельмана.pdf
Ligand- and Structure-Based Drug Design of NSAIs in Breast Cancer
Le Borgne, M., Marchand, P., Nourrisson, M. R., Loquet, D., Palzer, M., Le Baut, G., & Hartmann, R. W.
(2007). Synthesis and biological evaluation of 3-(azolylmethyl)-1H-indoles and 3-(alpha-azolylbenzyl)1H-indoles as selective aromatase inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry,
22(5), 667–676. doi:10.1080/14756360701652658 PMID:18035835
Le Brogne, M., Marchand, P., Delevove-Seiller, B., Robert, J. M., Le Baut, G., Hartmann, R. W., &
Palzer, M. (1999). New selective nonsteroidal aromatase inhibitors: Synthesis and inhibitory activity of
2,3 or 5-(alpha-azolylbenzyl)-1H-indoles. Bioorganic & Medicinal Chemistry Letters, 9(3), 333–336.
doi:10.1016/S0960-894X(98)00737-9 PMID:10091679
Le’ze´, M. P., Le Borgne, M., Marchand, P., Loquet, D., Kogler, M., & Le Bauta, G. etal. (2004). 2- and
3-[(aryl)(azolyl)methyl]indoles as potential non-steroidal aromatase inhibitors. Journal of Enzyme Inhi-
bition and Medicinal Chemistry, 19(6), 549–557. doi:10.1080/14756360400004631 PMID:15662958
Le’ze´, M. P., Le Borgne, M., Pinson, P., Palusczak, A., Duflos, M., Le Bauta, G., & Hartmann, R. W.
(2006). Synthesis and biological evaluation of 5-[(aryl)(1H-imidazol-1-yl)methyl]-1H-indoles: Potent
and selective aromatase inhibitors. Bioorganic & Medicinal Chemistry Letters, 16(5), 1134–1137.
doi:10.1016/j.bmcl.2005.11.099 PMID:16380254
Le’ze´, M. P., Palusczak, A., Hartmann, R. W., & Le Borgne, M. (2008). Synthesis of 6- or 4-functionalized indoles via a reductive cyclization approach and evaluation as aromatase inhibitors. Bioorganic
& Medicinal Chemistry Letters, 18(16), 4713–4715. doi:10.1016/j.bmcl.2008.06.094 PMID:18640836
Lengauer, T., & Rarey, M. (1996). Computational methods for biomolecular docking. Current Opinion
in Structural Biology, 6(3), 402–406. doi:10.1016/S0959-440X(96)80061-3 PMID:8804827
Leonetti, F., Favia, A., Rao, A., Aliano, R., Paluszcak, A., Hartmann, R. W., & Carotti, A. (2004). Design, synthesis, and 3D-QSAR of novel potent and selective aromatase inhibitors. Journal of Medicinal
Chemistry, 47(27), 6792–6803. doi:10.1021/jm049535j PMID:15615528
Lipton, A., Harvey, H. A., & Santen, R. J. (1982). Closing remarks to the conference, aromatase: New
perspectives for breast cancer. Cancer Research, 42(8), 3468s. PMID:7083210
Liu, F., Xie, Z. H., Cai, G. P., & Jiang, Y. Y. (2007). The effect of surviving on multidrug resistance
mediated by P-glycoprotein in MCF-7 and its adriamycin resistant cells. Biological & Pharmaceutical
Bulletin, 30(12), 2279–2283. doi:10.1248/bpb.30.2279 PMID:18057712
Lyman, G. H., Giuliano, A. E., & Somerfield, M. R. (2005). American society of clinical oncology
guideline recommendations for seminal lymph node biopsy in early-stage breast cancer. Journal of
Clinical Oncology, 23(30), 7703–7720. doi:10.1200/JCO.2005.08.001 PMID:16157938
Marchand, P., Le Borgne, M., Palzer, M., Le Bauta, G., & Hartmann, R. W. (2003). Preparation and
pharmacological profile of 7-(alpha-azolylbenzyl)-1H-indoles and indolines as new aromatase inhibitors.
Bioorganic & Medicinal Chemistry Letters, 13(9), 1553–1555. doi:10.1016/S0960-894X(03)00182-3
PMID:12699753
Martin, Y. C. (2000). DISCO: what we did right and what we missed. In O. F. Guner (Ed.), Pharmacophore
perception, development, and use in drug design (pp. 51–66). La Jolla, CA: International University Line.
456
EBSCOhost - printed on 2/14/2023 7:16 AM via . All use subject to https://www.ebsco.com/terms-of-use
Ligand- and Structure-Based Drug Design of NSAIs in Breast Cancer
Mauri, D., Pavlidis, N., & Loannidis, J. P. (2005). Neoadjuvant versus adjuvant systemic treatment in
breast cancer: A meta-analysis. Journal of the National Cancer Institute, 97(3), 188–194. doi:10.1093/
jnci/dji021 PMID:15687361
Mauri, D., Polyzos, N. P., Salanti, G., Pavlidis, N., & Ioannidis, J. P. (2008). Multiple treatments metaanalysis of chemotherapy and targeted therapies in advanced breast cancer. Journal of the National
Cancer Institute, 100(24), 1780–1791. doi:10.1093/jnci/djn414 PMID:19066278
May, F. E. B. (2014). Novel drugs that target the estrogen-related receptor alpha: Their therapeutic potential in breast cancer. Cancer Management and Research, 6, 225–252. doi:10.2147/CMAR.S35024
PMID:24904222
McCullough, L. E., Eng, S. M., Bradshaw, P. T., Cleveland, R. J., Teitelbaum, S. L., Neugut, A. I., &
Gammon, M. D. (2012). Fat or fit: The joint effects of physical activity, weight gain, and body size on
breast cancer risk. Cancer, 118(19), 4860–4868. doi:10.1002/cncr.27433 PMID:22733561
Michaelson, J., Satija, S., Moore, R., Weber, G., Halpern, E., & Garland, A. etal. (2002). The pattern of
breast cancer screening utilization and its consequences. Cancer, 94(1), 37–43. doi:10.1002/cncr.10154
PMID:11815958
Miller, K. D.(2012). Inhibiting telomerase to reverse trastuzumab(T) resistance in HER2+ breast cancer.
Cancer Research, 72(24 suppl).
Miller, W. R. (1997). Aromatase inhibitors and breast cancer. Cancer Treatment Reviews, 23(3), 171–187.
doi:10.1016/S0305-7372(97)90037-2 PMID:9251721
Miller, W. R. (2003). Aromatase inhibitors: Mechanism of action and role in the treatment of breast
cancer. Seminars in Oncology, 30(4-14), 3-11.
Miller, W. R., Bartlett, J., Brodie, A. M., Brueggemeier, R. W., di Salle, E., & Lonning, P. E. etal. (2008).
Aromatase inhibitors: Are there differences between steroidal and nonsteroidal aromatase inhibitors and
do they matter? The Oncologist, 13(8), 829–837. doi:10.1634/theoncologist.2008-0055 PMID:18695261
Miller, W. R., & O’neill, J. (1987). The importance of local synthesis of estrogen within the breast.
Steroids, 50(4-6), 537–548. doi:10.1016/0039-128X(87)90037-7 PMID:3504615
Modi, S., Saura, C., Henderson, C., Lin, N. U., Mahtani, R., & Goddard, J. etal. (2013). A multicenter
trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic
HER2-positive breast cancer. Breast Cancer Research and Treatment, 139(1), 107–113. doi:10.1007/
s10549-013-2510-5 PMID:23580070
Modi, S., Stopeck, A., Linden, H., Solit, D., Chandarlapaty, S., & Rosen, N. etal. (2011). HSP90 inhibition is effective in breast cancer: A phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients
with HER2-positive metastatic breast cancer progressing on trastuzumab. Clinical Cancer Research,
17(15), 5132–5139. doi:10.1158/1078-0432.CCR-11-0072 PMID:21558407
Mohammed, H. A., Ba, L. A., Burkholz, T., Schumann, E., Diesel, B., & Zapp, J. etal. (2011). Facile
synthesis of chrysin-derivatives with promising activities as aromatase inhibitors. Natural Product Com-
munications, 6(1), 31–34. PMID:21366040
EBSCOhost - printed on 2/14/2023 7:16 AM via . All use subject to https://www.ebsco.com/terms-of-use
457
Ligand- and Structure-Based Drug Design of NSAIs in Breast Cancer
Mohan, V., Gibbs, A. C., Cummings, M. D., Jaeger, E. P., & DesJarlais, R. L. (2005). Docking: Successes and challenges. Current Pharmaceutical Design, 11(3), 323–333. doi:10.2174/1381612053382106
PMID:15723628
Morales, A., Buvat, J., Gooren, L. J., Guav, A. T., Kaufman, J. M., Tan, H. M., & Torres, L. O. (2004).
Endocrine aspects of sexual dysfunction in men. Journal of Sexual Medicine, 1(1), 69–81. doi:10.1111/
j.1743-6109.2004.10111.x PMID:16422986
Muftuoglu, Y., & Mustata, G. (2010). Pharmacophore modeling strategies for the development of novel
nonsteroidal inhibitors of human aromatase (CYP19). Bioorganic & Medicinal Chemistry Letters, 20(10),
3050–3064. doi:10.1016/j.bmcl.2010.03.113 PMID:20413308
Murthy, J. N., Nagaraju, M., Sastry, G. M., Rao, A. R., & Sastry, G. N. (2006). Active site acidic residues
and structural analysis of modeled human aromatase: A potential drug target for breast cancer. Journal of
Computer-Aided Molecular Design, 19(12), 857–870. doi:10.1007/s10822-005-9024-0 PMID:16741831
Murthy, J. N., Rao, A. R., & Sastry, G. N. (2004). Aromatase inhibitors: A new paradigm in breast cancer treatment. Current Medicinal Chemistry. Anti-Cancer Agents, 4(6), 523–534. doi:10.2174/1568011043352669
PMID:15579017
Muti, P., Rogan, E., & Cavalieri, E. (2006). Androgens and estrogens in the etiology and prevention of
breast cancer. Nutrition and Cancer, 56(2), 247–252. doi:10.1207/s15327914nc5602_17 PMID:17474872
Nagar, S., Islam, M. A., Das, S., Mukherjee, A., & Saha, A. (2008). Pharmacophore mapping of flavone
derivatives for aromatase inhibition. Molecular Diversity, 12(1), 65–76. doi:10.1007/s11030-008-9077-9
PMID:18506592
Nagar, S., Islam, M. A., Das, S., Mukherjee, A., & Saha, A. (2009). Pharmacophore searching of benzofuran derivatives for selective CYP19 aromatase inhibition. Letters in Drug Design & Discovery, 6(1),
38–45. doi:10.2174/157018009787158607
Nagar, S., & Saha, A. (2010a). Exploring benzcyclo derivatives as potent aromatase inhibitors using ligandbased modeling studies. European Journal of Medicinal Chemistry, 45(9), 4307–4315. doi:10.1016/j.
ejmech.2010.06.033 PMID:20638757
Nagar, S., & Saha, A. (2010b). Modeling of diarylalkyl-imidazole and diarylalkyl-triazole derivatives
as potent aromatase inhibitors for treatment of hormone-dependent cancer. Journal of Computational
Chemistry, 31(12), 2342–2353. PMID:20340106
Nagar, S., & Saha, A. (2010c). QSAR modeling and pharmacophore mapping of isoflavone derivatives
for aromatase inhibitory activity. International Journal of Pharmacy and Pharmaceutical Sciences,
2(3), 126–131.
Nagy, P. I., Tokarski, J., & Hopfinger, A. J. (1994). Molecular shape and QSAR analyses of a family
of substituted dichlorodiphenyl aromatase inhibitors. Journal of Chemical Information and Computer
Sciences, 34(5), 1190–1197. doi:10.1021/ci00021a029 PMID:7962215
458
EBSCOhost - printed on 2/14/2023 7:16 AM via . All use subject to https://www.ebsco.com/terms-of-use
Ligand- and Structure-Based Drug Design of NSAIs in Breast Cancer
Nahta, R., Yuan, L. X., Zhang, B., Kobayashi, R., & Esteva, F. J. (2005). Insulin-like growth factor- I
receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Research, 65(23), 11118–11128. doi:10.1158/0008-5472.CAN-
04-3841 PMID:16322262
Nakshatri, H., Bhat-Nakshatri, P., Martin, D. A., Goulet, R. J. Jr, & Sledge, G. W. Jr. (1997). Constitutive
activation of NF-kappaB during progression of breast cancer to hormone-dependent growth. Molecular
and Cellular Biology, 17(7), 3629–3639. PMID:9199297
Nantasenamat, C., Li, H., Mandi, P., Worachartcheewan, A., Monnor, T., Ayudhya, C. I. N., & Prachayasittikul, V. (2013). Exploring the chemical space of aromatase inhibitors. Molecular Diversity, 17(4),
661–677. doi:10.1007/s11030-013-9462-x PMID:23857318
Nantasenamat, C., Worachartcheewan, A., Mandi, P., Monnor, T., Ayudhya, C. I. N., & Prachayasittikul,
V. (2014). QSAR modeling of aromatase inhibition by flavonoids using machine learning approaches.
Chemical Papers, 68(5), 697–713. doi:10.2478/s11696-013-0498-2
Nantasenamat, C., Worachartcheewan, A., Prachayasittikul, S., Ayudhya, C. I. N., & Prachayasittikul,
V. (2013). QSAR modeling of aromatase inhibitory activity of 1-substituted 1, 2, 3-triazole analogs of
letrozole. European Journal of Medicinal Chemistry, 69(1), 99–114. doi:10.1016/j.ejmech.2013.08.015
PMID:24012714
Narayana, B. L., Kishore, D. P., Balakumar, C., Rao, K. V., Kaur, R., & Rao, A. R. etal. (2012). Molecular modeling evaluation of non-steroidal aromatase inhibitors. Chemical Biology & Drug Design,
79(5), 674–682. doi:10.1111/j.1747-0285.2011.01277.x PMID:22129073
Neves, M. A., Dinis, T. C., Colombo, G., & Sae Melo, M. L. (2009a). An efficient steroid pharmacophorebased strategy to identify new aromatase inhibitors. European Journal of Medicinal Chemistry, 44(10),
4121–4127. doi:10.1016/j.ejmech.2009.05.003 PMID:19500885
Neves, M. A., Dinis, T. C., Colombo, G., & Sae Melo, M. L. (2009b). Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. Journal of Medicinal Chemistry,
52(1), 143–150. doi:10.1021/jm800945c PMID:19072235
Numazawa, M., Shelangouski, M., & Nagasaka, M. (2000). Probing the binding pocket of the active site
of aromatase with 6-ether or 6-ester substituted androst-4-ene-3,17-diones and their diene and triene
analogs. Steroids, 65(12), 871–882. doi:10.1016/S0039-128X(00)00169-0 PMID:11077085
Numazawa, M., Yamada, K., Watari, Y., & Ando, M. (2002). Improved synthesis and molecular modeling
of 4β, 19-dihydroxyandrost-5-ene-17-one, an excellent inhibitor of aromatase. Chemical & Pharmaceuti-
cal Bulletin, 50(5), 703–705. doi:10.1248/cpb.50.703 PMID:12036037
Okada, M., Yoden, T., Kawaminami, E., Shimada, Y., Kudoh, M., & Isomura, Y. (1997a). Studies on
aromatase inhibitors. II. Synthesis and biological evaluation of 1-amino-1H-1, 2, 4-triazole derivatives.
Chemical & Pharmaceutical Bulletin, 45(2), 333–337. doi:10.1248/cpb.45.333 PMID:9118448
EBSCOhost - printed on 2/14/2023 7:16 AM via . All use subject to https://www.ebsco.com/terms-of-use
459
Ligand- and Structure-Based Drug Design of NSAIs in Breast Cancer
Okada, M., Yoden, T., Kawaminami, E., Shimada, Y., Kudoh, M., & Isomura, Y. (1997b). Studies on
aromatase inhibitors. III. Synthesis and biological evaluation of [(4-bromobenzyl) (4-cyanophenyl)
amino]azole and their azine analogs. Chemical & Pharmaceutical Bulletin, 45(3), 482–486. doi:10.1248/
cpb.45.482 PMID:9085555
Okada, M., Yoden, T., Kawaminami, E., Shimada, Y., Kudoh, M., & Isomura, Y. (1997c). Studies on
aromatase inhibitors. IV. Synthesis and biological evaluation of N, N-disubstituted-5-aminopyrimidine derivatives. Chemical & Pharmaceutical Bulletin, 45(8), 1293–1299. doi:10.1248/cpb.45.1293
PMID:9301028
Okada, M., Yoden, T., Kawaminami, E., Shimada, Y., Kudoh, M., & Isomura, Y. etal. (1996). Studies on
aromatase inhibitors. I. Synthesis and biological evaluation of 4-amino-4H-1, 2, 4-triazole derivatives.
Chemical & Pharmaceutical Bulletin, 44(10), 1871–1879. doi:10.1248/cpb.44.1871 PMID:8904814
Ortuso, F., Langer, T., & Alcaro, S. (2006). GBPM: GRID based pharmacophore model, concept and
application studies to protein-protein recognition. Bioinformatics (Oxford, England), 22(12), 1449–1455.
doi:10.1093/bioinformatics/btl115 PMID:16567363
Osborne, C., & Tripathy, D. (2005). Aromatase inhibitors: Rationale and use in breast cancer. Annual
Review of Medicine, 56(1), 103–116. doi:10.1146/annurev.med.56.062804.103324 PMID:15660504
Osborne, C. K., & Schiff, R. (2005). Aromatase inhibitors: Future directions. The Journal of Steroid Bio-
chemistry and Molecular Biology, 95(1-5), 183–187. doi:10.1016/j.jsbmb.2005.04.021 PMID:16019204
Pasqualini, J. R. (2004). The selective estrogen enzyme modulators in breast cancer: A review. Biochi-
mica et Biophysica Acta, 1654(2), 123–143. PMID:15172700
Pasqualini, J. R., Chetrite, G., Blacker, C., Feinstein, M. C., Delalonde, L., Talbi, M., & Maloche, C.
(1996). Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase
activities in pre- and postmenopausal breast cancer patients. The Journal of Clinical Endocrinology and
Metabolism, 81(4), 1460–1464. PMID:8636351
Petkov, P. I., Temelkov, S., Villeneuve, D. L., Ankley, G. T., & Mekenyan, O. G. (2009). Mechanismbased categorization of aromatase inhibitors: A potential discovery and screening tool. SAR and QSAR
in Environmental Research, 20(7–8), 657–678. doi:10.1080/10629360903438347 PMID:20024803
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., & Smith, I. etal.
(2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. The New England
Journal of Medicine, 353(16), 1659–1672. doi:10.1056/NEJMoa052306 PMID:16236737
Plourde, P. V., Dyroff, M., & Dukes, M. (1994). Arimdex: A potent and selective fourth generation
aromatase inhibitor. Breast Cancer Research and Treatment, 30(1), 103–111. doi:10.1007/BF00682745
PMID:7949201
Polanski, J., & Gieleciak, R. (2003). The comparative molecular surface analysis (CoMSA) with modified uniformative variable elimination-PLS (UVE-PLS) Method: Application to the steroids binding
the aromatase enzyme. Journal of Chemical Information and Computer Sciences, 43(2), 656–666.
doi:10.1021/ci020038q PMID:12653535
460
EBSCOhost - printed on 2/14/2023 7:16 AM via . All use subject to https://www.ebsco.com/terms-of-use
Ligand- and Structure-Based Drug Design of NSAIs in Breast Cancer
Pouget, C., Fagnere, C., Basly, J. P., Besson, A. E., Champavier, Y., Habrioux, G., & Chulia, A. J. (2002c).
Synthesis and aromatase inhibitory activity of flavanones. Pharmaceutical Research, 19(3), 286–291.
doi:10.1023/A:1014490817731 PMID:11934235
Pouget, C., Fagnere, C., Basly, J. P., Habrioux, G., & Chulia, A. J. (2002a). Design, synthesis and evaluation of 4-imidazolylflavans as new leads for aromatase inhibition. Bioorganic & Medicinal Chemistry
Letters, 12(20), 2859–2861. doi:10.1016/S0960-894X(02)00565-6 PMID:12270163
Pouget, C., Fagnere, C., Basly, J. P., Habrioux, G., & Chulia, A. J. (2002b). New aromatase inhibitors.
synthesis and inhibitory activity of pyridinyl-substituted flavanone derivatives. Bioorganic & Medicinal
Chemistry Letters, 12(7), 1059–1061. doi:10.1016/S0960-894X(02)00072-0 PMID:11909717
Pouget, C., Yahiaoui, S., Fagnere, C., Habrioux, G., & Chulia, A. J. (2004). Synthesis and biological
evaluation of 4-imidazolylflavans as nonsteroidal aromatase inhibitors. Bioorganic Chemistry, 32(6),
494–503. doi:10.1016/j.bioorg.2004.06.008 PMID:15530990
Proteau, P. J. (2011). Steroid hormones and therapeutically related compounds. In Wilson and Gisvold’s
textbook of organic medicinal and pharmaceutical chemistry (pp. 819-867). Philadelphia: Lipincott
Williams and Wilkins.
Recanatini, M. (1996). Comparative molecular field analysis of non-steroidal aromatase inhibitors related
to fadrozole. Journal of Computer-Aided Molecular Design, 10(1), 74–82. doi:10.1007/BF00124467
PMID:8786417
Recanatini, M., Bisi, A., Cavalli, A., Belluti, F., Gobbi, S., & Rampa, A. etal. (2001). A new class of
nonsteroidal aromatase inhibitors: Design and synthesis of chromone and xanthone derivatives and
inhibition of the P450 enzymes aromatase and 17r-hydroxylase/C17, 20-lyase. Journal of Medicinal
Chemistry, 44(5), 672–680. doi:10.1021/jm000955s PMID:11262078
Recanatini, M., & Cavalli, A. (1998). Comparative molecular field analysis of non-steroidal aromatase
inhibitors: An extended model for two different structural classes. Bioorganic & Medicinal Chemistry,
6(4), 377–388. doi:10.1016/S0968-0896(97)10053-0 PMID:9597182
Recanatini, M., Cavalli, A., & Valenti, P. (2002). Nonsteroidal aromatase inhibitors: Recent advances.
Medicinal Research Reviews, 22(3), 282–304. doi:10.1002/med.10010 PMID:11933021
Reed, M. J., Owen, A. M., Lai, L. C., Coldham, N. G., Ghilchik, M. W., Shaikh, N. A., & James, V. H.
(1989). In situ estrogen synthesis in normal breast and breast tumor tissues: Effect of treatment with
4-hydroxyandrostenedione. International Journal of Cancer, 44(2), 233–237. doi:10.1002/ijc.2910440208
PMID:2759729
Rollinger, J. M., Hornick, A., Langer, T., Stuppner, H., & Prast, H. (2004). Acetylcholinesterase inhibitory activity of scopolin and scopolectin discovered by virtual screening of natural products. Journal of
Medicinal Chemistry, 47(25), 6248–6254. doi:10.1021/jm049655r PMID:15566295
Roy, P. P., & Roy, K. (2010a). Molecular docking and QSAR studies of aromatase inhibitor androstenedione derivatives. The Journal of Pharmacy and Pharmacology, 62(12), 1717–1728. doi:10.1111/j.2042-
7158.2010.01154.x PMID:21054398
EBSCOhost - printed on 2/14/2023 7:16 AM via . All use subject to https://www.ebsco.com/terms-of-use
461
Ligand- and Structure-Based Drug Design of NSAIs in Breast Cancer
Roy, P. P., & Roy, K. (2010b). Docking and 3D-QSAR studies of diverse classes of human aromatase
(CYP19) inhibitors. Journal of Molecular Modeling, 16(10), 1597–1616. doi:10.1007/s00894-0100667-y PMID:20195667
Ryan, B. M., Konecny, G. E., Kahlert, S., Wang, H. J., Untch, M., & Meng, G. etal. (2006). Survivin
expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase
plasminogen activator and PAI-1. Annals of Oncology, 17(4), 597–604. doi:10.1093/annonc/mdj121
PMID:16403812
Saberi, M. R., Shah, K., & Simons, C. (2005). Benzofuran- and furan-2-yl-(phenyl)-3-pyridylmethanols:
Synthesis and inhibition of P450 aromatase. Journal of Enzyme Inhibition and Medicinal Chemistry,
20(2), 135–141. doi:10.1080/14756360400015256 PMID:15968818
Saberi, M. R., Vinh, T. K., Yee, S. W., Griffiths, B. J., Evans, P. J., & Simons, C. (2006). Potent CYP19
(aromatase) 1-[(Benzofuran-2-yl)(phenylmethyl)pyridine, -imidazole, and -triazole inhibitors: Synthesis
and biological evaluation. Journal of Medicinal Chemistry, 49(3), 1016–1022. doi:10.1021/jm0508282
PMID:16451067
Santen, R. J., & Harvey, H. A. (1999). Use of aromatase inhibitors in breast carcinoma. Endocrine-
Related Cancer, 6(1), 75–92. doi:10.1677/erc.0.0060075 PMID:10732791
Schlotter, C. M., Vogt, U., Allgayer, H., & Brandt, B. (2008). Molecular targeted therapies for breast
cancer treatment. Breast Cancer Research, 10(4), 211. doi:10.1186/bcr2112 PMID:18671839
Schuster, D., Laggner, C., Steindl, T. M., Palusczak, A., Hartmann, R. W., & Langer, T. (2006). Pharmacophore modeling and in silico screening for new P450 19 (aromatase) inhibitors. Journal of Chemical
Information and Modeling, 46(3), 1301–1311. doi:10.1021/ci050237k PMID:16711749
Schwarzel, W. C., Kruggel, W. G., & Brodie, H. J. (1973). Studies on the mechanism of estrogen biosynthesis. 8. The development of inhibitors of the enzyme system in human placenta. Endocrinology,
92(3), 866–880. doi:10.1210/endo-92-3-866 PMID:4267111
Seralini, G. E., & Moslemi, S. (2001). Aromatase inhibitors: Past, present and future. Molecular and
Cellular Endocrinology, 178(1-2), 117–131. doi:10.1016/S0303-7207(01)00433-6 PMID:11403901
Serpentini, C. N., Moslemi, S., Yous, S., Park, C. H., Lesieur, D., Sourdaine, P., & Seralini, G. E. (2004).
Synthesis and evaluation of benzoxazolinoic imidazoles and derivatives of non-steroidal aromatase
inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 19(2), 119–127. doi:10.1080/1475
6360410001667319 PMID:15449726
Shaikh, S. A., Jain, T., Sandhu, G., Latha, N., & Jayaram, B. (2007). From drug target to leads-sketching
a physicochemical pathway for lead molecule design in silico. Current Pharmaceutical Design, 13(34),
3454–3470. doi:10.2174/138161207782794220 PMID:18220783
Shimozawa, O., Sakaguchi, M., Ogawa, H., Harada, N., Mihara, K., & Omura, T. (1993). Core glycosylation of cytochrome P-450(arom). Evidence for localization of N terminus of microsomal cytochrome
P-450 in the lumen. The Journal of Biological Chemistry, 268(28), 21399–21402. PMID:8407981
462
EBSCOhost - printed on 2/14/2023 7:16 AM via . All use subject to https://www.ebsco.com/terms-of-use
Ligand- and Structure-Based Drug Design of NSAIs in Breast Cancer
Siegel, R., Naishadham, D., & Jemal, A. (2012). Cancer statistics, 2012. CA: a Cancer Journal for
Clinicians, 62(1), 10–29. doi:10.3322/caac.20138 PMID:22237781
Simpson, E. R., Clyne, C., Rubin, G., Boon, W. C., Robertson, K., & Britt, K. etal. (2002). Aromatase-a brief
overview. Annual Review of Physiology, 64(1), 93–127. doi:10.1146/annurev.physiol.64.081601.142703
PMID:11826265
Simpson, E. R., & Davis, S. R. (2001). Minireview: Aromatase and the regulation of estrogen biosynthesissome new perspectives. Endocrinology, 142(11), 4589–4594. PMID:11606422
Simpson, E. R., Mahandroo, M. S., Means, G. D., Kilgore, M. W., Hinshelwood, M. M., & GrahamLorence, S. etal. (1994). Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis.
Endocrine Reviews, 15(3), 342–355. PMID:8076586
Simpson, E. R., Mahendroo, M. S., Means, G. D., Kilgore, M. W., Corbin, C. J., & Maldelson, C. R.
(1993). Tissue-specific promoters regulate aromatase cytochrome P450 expression. The Journal of
Steroid Biochemistry and Molecular Biology, 44(4-6), 321–330. doi:10.1016/0960-0760(93)90235-O
PMID:8476746
Sitteri, P. K., & Thompson, E. A. (1975). Studies of human placental aromatase. Journal of Steroid
Biochemistry, 6(3-4), 317–322. doi:10.1016/0022-4731(75)90149-1 PMID:810626
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., & Bajamonde, A. etal. (2001). Use of
chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses
HER2. The New England Journal of Medicine, 344(11), 783–792. doi:10.1056/NEJM200103153441101
PMID:11248153
Smith, I. E., & Dowsett, M. (2003). Aromatase inhibitors in breast cancer. The New England Journal of
Medicine, 348(24), 2431–2442. doi:10.1056/NEJMra023246 PMID:12802030
Spinelli, G. P., Tomao, F., Miele, E., Pasciuti, G., Russillo, M., & Tomao, S. (2008). Aromatase inhibitors in advanced breast cancer. Recenti Progressi in Medicina, 99(1), 34–38. PMID:18389871
Stefanachi, A., Favia, A. D., Nicolotti, O., Leonetti, F., Pisani, L., & Catto, M. etal. (2011). Design,
synthesis, and biological evaluation of imidazolyl derivatives of 4,7-disubstituted coumarins as aromatase inhibitors selective over 17-α-hydroxylase/C17-20 lyase. Journal of Medicinal Chemistry, 54(6),
1613–1625. doi:10.1021/jm101120u PMID:21341743
Steindl, T. M., Schuster, D., Laggner, C., & Langer, T. (2006). Parallel screening: A novel concept in
pharmacophore modeling and virtual screening. Journal of Chemical Information and Modeling, 46(5),
2146–2157. doi:10.1021/ci6002043 PMID:16995745
Su, B., Hackett, J. C., Diaz-Cruz, E. S., Kim, Y. W., & Brueggemeier, R. W. (2005). Lead optimization of 7-benzyloxy 2-(40-pyridylmethyl)thio isoflavone aromatase inhibitors. Bioorganic & Medicinal
Chemistry, 13(23), 6571–6577. doi:10.1016/j.bmc.2005.07.038 PMID:16125392
EBSCOhost - printed on 2/14/2023 7:16 AM via . All use subject to https://www.ebsco.com/terms-of-use
463
Ligand- and Structure-Based Drug Design of NSAIs in Breast Cancer
Sun, B., Hoshino, J., Jermihov, K., Marler, L., Pezzuto, J. M., Mesecar, A. D., & Cushman, M. (2010).
Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase
2 inhibitors for chemoprevention of cancer. Bioorganic & Medicinal Chemistry, 18(14), 5352–5366.
doi:10.1016/j.bmc.2010.05.042 PMID:20558073
Taylor, H. M., Jones, C. D., Davenport, J. D., Hirsch, K. S., Kress, T. J., & Weaver, D. (1987). Aromatase
inhibition by 5-substituted pyrimidines and dihydropyrimidines. Journal of Medicinal Chemistry, 30(8),
1359–1365. doi:10.1021/jm00391a016 PMID:3612685
Tintori, C., Corradi, V., Magnani, M., Manetti, F., & Botta, M. (2008). Targets looking for drugs: A
multistep computational protocol for the development of structure based pharmacophores and their
applications for hit discovery. Journal of Chemical Information and Modeling, 48(11), 2166–2179.
doi:10.1021/ci800105p PMID:18942779
Tripos Inc. SYBYL-X 2.0, 1699 South Hanley Road, St. Louis, MO. 63144. USA, 2012.
Trunet, P. F., Vreeland, F., Royce, C., Chaudri, H. A., Cooper, J., & Bhatnagar, A. (1997). Clinical uses
of aromatase inhibitors in the treatment of advanced breast cancer. The Journal of Steroid Biochemistry
and Molecular Biology, 61(3-6), 241–245. doi:10.1016/S0960-0760(97)80018-0 PMID:9365196
Ulmschneider, S., Muller-Vieira, U., Klein, C. D., Antes, I., Lengauer, T., & Hartmann, R. W. (2005).
Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: Potent and selective inhibitors of aldosterone synthase. Journal of Medicinal Chemistry,
48(5), 1563–1575. doi:10.1021/jm0492397 PMID:15743198
Vinh, T. K., Ahmadi, M., Delgado, P. O., Perez, S. F., Walters, H. M., & Smith, H. J. etal. (1999).
1-[(Benzofuran-2-yl)phenylmethyl]-triazoles and -tetrazoles - potent competitive inhibitors of aromatase.
Bioorganic & Medicinal Chemistry Letters, 9(14), 2105–2108. doi:10.1016/S0960-894X(99)00328-5
PMID:10450990
Vinh, T. K., Yee, S. W., Kirby, A. J., Nicholls, P. J., & Simons, C. (2001). 1-[(Benzofuran-2-yl) phenylmethyl] triazoles as steroidogenic inhibitors:synthesis and in vitro inhibition of placental CYP19 aromatase. Anti-Cancer Drug Design, 16(4-5), 217-25.
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., & Fehrenbacher, L. etal. (2002).
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing
metastatic breast cancer. Journal of Clinical Oncology, 20(3), 719–726. doi:10.1200/JCO.20.3.719
PMID:11821453
Wächter, G. A., Hartmann, R. W., Sergejew, T., Grun, G. L., & Ledergerber, D. (1996). Tetrahydronaphthalenes: Influence of heterocyclic substituents on inhibition of steroidogenic enzymes P450 arom
and P450 17. Journal of Medicinal Chemistry, 39(4), 834–841. doi:10.1021/jm950377t PMID:8632407
Wei, D., Jiang, X., Zhou, L., Chen, J., Chen, Z., & He, C. etal. (2008). Discovery of multi-target inhibitors by combining molecular docking with common pharmacophore matching. Journal of Medicinal
Chemistry, 51(24), 7882–7888. doi:10.1021/jm8010096 PMID:19090779
464
EBSCOhost - printed on 2/14/2023 7:16 AM via . All use subject to https://www.ebsco.com/terms-of-use
Ligand- and Structure-Based Drug Design of NSAIs in Breast Cancer
Westley, R. L., & May, F. E. B. (2013). A twenty-first century cancer epidemic caused by obesity: The
involvement of insulin, diabetes, and insulin-like growth factors. International Journal of Endocrinol-
ogy, 632461. PMID:23983688
Whomsley, R. F., Fernandez, E., Nicholls, P. J., Smith, H. J., Lombardi, P., & Pestillini, V. (1993). Substituted 1-[(Benzofuran-2-yl) phenylmethyl] imidazoles as potent inhibitors of aromatase in vitro and
in female rats in vivo. The Journal of Steroid Biochemistry and Molecular Biology, 44(4-6), 675–676.
doi:10.1016/0960-0760(93)90279-6 PMID:8476782
Wolber, G., & Langer, T. (2005). LigandScout: 3D pharmacophores derived from protein bound ligands
and their use as virtual screening filters. Journal of Chemical Information and Modeling, 45(1), 160–169.
doi:10.1021/ci049885e PMID:15667141
Woo, L. W. L., Bubert, C., Sutcliffe, O. B., Smith, A., Chander, S. K., & Mahon, M. F. etal. (2007). Dual
aromatase-steroid sulfatase inhibitors. Journal of Medicinal Chemistry, 50(15), 3540–3560. doi:10.1021/
jm061462b PMID:17580845
Woo, L. W. L., Jackson, T., Putey, A., Cozier, G., Leonard, P., & Acharya, K. R. etal. (2010). Highly
potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template. Journal
of Medicinal Chemistry, 53(5), 2155–2170. doi:10.1021/jm901705h PMID:20148564
Woo, L. W. L., Sutcliffe, O. B., Bubert, C., Grasso, A., Chander, S. K., & Purohit, A. etal. (2003).
First dual aromatase-steroid sulfatase inhibitors. Journal of Medicinal Chemistry, 46(15), 3193–3196.
doi:10.1021/jm034033b PMID:12852749
Wood, P. M., Woo, L. W. L., Humphreys, A., Chander, S. K., Purohit, A., Reed, M. J., & Potter, B.
V. L. (2005). A letrozole-based dual aromatase-sulphatase inhibitor with in vivo activity. The Journal
of Steroid Biochemistry and Molecular Biology, 94(1-3), 123–130. doi:10.1016/j.jsbmb.2004.12.028
PMID:15862957
Wood, P. M., Woo, L. W. L., Labrosse, J. R., Thomas, M. P., Mahon, M. F., & Chander, S. K. etal. (2010).
Bicyclic derivatives of the potent dual aromatase-steroid sulfatase inhibitor 2-Bromo-4-{[(4-cyanophenyl)
(4H-1, 2, 4-triazol-4-yl) amino] methyl} phenylsulfamate: Synthesis, SAR crystal structure, and in vitro
and in vivo activities. ChemMedChem, 5(9), 1577–1593. doi:10.1002/cmdc.201000203 PMID:20632362
Wood, P. M., Woo, L. W. L., Labrosse, J. R., Trusselle, M. N., Abbate, S., & Longhi, G. etal. (2008).
Chiral aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole template: Synthesis, absolute configuration, and in vitro activity. Journal of Medicinal Chemistry, 51(14), 4226–4238.
doi:10.1021/jm800168s PMID:18590272
Worachartcheewan, A., Mandi, P., Prachayasittikul, V., Toropova, A. P., Toropov, A. A., & Nantasenamat, C. (2014). Large-scale QSAR study of aromatase inhibitors using SMILES-based descriptors.
Chemometrics and Intelligent Laboratory Systems, 138(1), 120–126. doi:10.1016/j.chemolab.2014.07.017
Yahiaoui, S., Pouget, C., Fagnere, C., Champavier, Y., Habriouxa, G., & Chulia, A. J. (2004). Synthesis
and evaluation of 4-triazolylflavans as new aromatase inhibitors. Bioorganic & Medicinal Chemistry
Letters, 14(20), 5215–5218. doi:10.1016/j.bmcl.2004.07.090 PMID:15380230
EBSCOhost - printed on 2/14/2023 7:16 AM via . All use subject to https://www.ebsco.com/terms-of-use
465